Overview

Long-term Extension Study of Ligelizumab in Food Allergy

Status:
Not yet recruiting
Trial end date:
2029-07-20
Target enrollment:
Participant gender:
Summary
This is an extension study to evaluate the long-term safety and efficacy of ligelizumab in particiants who have completed a ligelizumab Phase III study in food allergy.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Antibodies, Anti-Idiotypic